Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVP-6124 26-week extension study in Alzheimer's disease
2013-002654-75Phase 3Terminated
- Sponsor
- FORUM Pharmaceuticals
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of encenicline in Alzheimer's disease (AD) (2 arms), sponsored by FORUM Pharmaceuticals. Primary endpoints: Mini-Mental State Examination and Neuropsychiatric Inventory. Started May 2014; status: terminated.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2013-002654-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002654-75.